PF-Atlas › Mechanisms › First-in-class TNIK kinase inhibitor — blocks TRAF2/NCK-interacting kinase driving fibrosis and inflammation
First-in-class TNIK kinase inhibitor — blocks TRAF2/NCK-interacting kinase driving fibrosis and inflammation in IPF
Mechanism of action · idiopathic pulmonary fibrosis
Overview
First-in-class TNIK kinase inhibitor — blocks TRAF2/NCK-interacting kinase driving fibrosis and inflammation is a therapeutic target in idiopathic pulmonary fibrosis. PF-Atlas tracks 1 drug and 0 clinical trials acting through this mechanism.
Drugs targeting First-in-class TNIK kinase inhibitor — blocks TRAF2/NCK-interacting kinase driving fibrosis and inflammation
Therapies
Medical disclaimer. This is a research summary, not medical advice.